ATX inhibitor BBT-877

Also Known As:

BBT-877

Networked: 1 relevant articles (1 outcomes, 0 trials/studies)

1.	Inflammation (Inflammations) 01/01/2022 - "In conclusion, our results indicate that BBT-877 is effective in preventing the pathogenesis of DN by reducing systemic blood glucose levels and inhibiting inflammation and fibrosis in the renal tissue of diabetes mice. "
2.	Fibrosis (Cirrhosis) 01/01/2022 - "In conclusion, our results indicate that BBT-877 is effective in preventing the pathogenesis of DN by reducing systemic blood glucose levels and inhibiting inflammation and fibrosis in the renal tissue of diabetes mice. "
3.	Dyslipidemias (Dyslipidemia) 01/01/2022 - "Interestingly, BBT-877 treatment attenuated hyperglycemia and dyslipidemia in STZ-induced diabetes mice. "
4.	Hyperglycemia 01/01/2022 - "Interestingly, BBT-877 treatment attenuated hyperglycemia and dyslipidemia in STZ-induced diabetes mice. "
5.	Diabetic Nephropathies (Diabetic Nephropathy) 01/01/2022 - "Effect of BBT-877, a novel inhibitor of ATX, on a mouse model of type 1 diabetic nephropathy."